This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Arvinas (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
by Zacks Equity Research
Novartis (NVS) comfortably beats first-quarter earnings and sales estimates. The company ups its outlook for 2024 on strong growth across key brands.
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
by Zacks Equity Research
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
Is Arvinas (ARVN) Stock a Solid Choice Right Now?
by Kaibalya Pravo Dey
Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Is a Surprise Coming for Arvinas (ARVN) This Earnings Season?
by Zacks Equity Research
Arvinas (ARVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -90.23% and 210.76%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 30.2% upside potential for Arvinas, Inc. (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Arvinas, Inc. (ARVN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Can Tenet's (THC) Q4 Earnings Beat on Rising Patient Admissions?
by Zacks Equity Research
Tenet's (THC) fourth-quarter results are likely to reflect higher Ambulatory Care operating revenues and supply costs.
Wall Street Analysts Think Arvinas, Inc. (ARVN) Could Surge 26.67%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in Arvinas, Inc. (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Encompass Health (EHC) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Encompass Health's (EHC) fourth-quarter results are likely to reflect pricing increases and growing volumes.
Arvinas, Inc. (ARVN) Soars 10.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Will High Medical Costs Affect Centene's (CNC) Q4 Earnings?
by Zacks Equity Research
Centene's (CNC) fourth-quarter results are likely to reflect growth in premiums and overall memberships.
Cigna (CI) to Report Q4 Earnings: Can Rising Expenses Hurt?
by Zacks Equity Research
Cigna's (CI) fourth-quarter results are likely to reflect growth in Evernorth revenues and customer base.
Can Higher Costs Affect HCA Healthcare's (HCA) Q4 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) fourth-quarter results are likely to reflect increased admissions and a lower average length of stay.
Can Higher Costs Affect Elevance Health's (ELV) Q4 Earnings?
by Zacks Equity Research
Elevance Health's (ELV) fourth-quarter results are likely to reflect higher premiums and product revenues.
What Makes Arvinas, Inc. (ARVN) a New Strong Buy Stock
by Zacks Equity Research
Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Arvinas, Inc. (ARVN) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Is Arvinas (ARVN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Arvinas, Inc. (ARVN) and ImmunoGen (IMGN) have performed compared to their sector so far this year.
Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 42.1% upside potential for Arvinas, Inc. (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Has Arvinas (ARVN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Arvinas, Inc. (ARVN) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study
by Zacks Equity Research
Interim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patients.
Does Arvinas, Inc. (ARVN) Have the Potential to Rally 145.52% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 145.5% in Arvinas, Inc. (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Predict a 165.07% Upside in Arvinas, Inc. (ARVN): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Arvinas, Inc. (ARVN) points to a 165.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Arvinas, Inc. (ARVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Arvinas, Inc. (ARVN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.